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as lower amputation rates (BLCC: -27.6% p= 0.04, HFDS: -22.2% p= 0.19) during the 
18-month follow-up period. While BLCC and HFDS patients did have higher costs 
for outpatient services (BLCC: +$7,100 p< 0.01, HFDS: +$11,947 p< 0.01), overall, these 
patients had lower average per-patient healthcare costs during the 18-month follow-
up period compared with their respective matched CC counterparts (BLCC: -$5,253 
p= 0.49, HFDS: -$6,991 p= 0.84). ConClusions: These findings suggest that use of 
BLCC and HFDS for treatment of DFU may lower overall medical costs through 
reduced utilization of costly healthcare services.
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objeCtives: In the recent Pathway CH-1 study, on-demand stimulation of the sphe-
nopalatine ganglion (SPG) by means of an implantable neurostimulation system was 
proven to be a safe and effective therapy for the treatment of chronic cluster head-
ache. Our objective was to assess the cost-effectiveness of SPG stimulation in the 
German healthcare system when compared to medical management. Methods: 
Clinical data from the Pathway CH-1 study were used as input for a model-based 
projection of the cost-effectiveness of SPG stimulation through 5 years. Medical 
management as the comparator treatment was modeled on the basis of clinical 
events observed during the baseline period of CH-1. The costs of treatment were 
derived from a previously published cluster headache costing study and2014 medi-
cation, neurostimulator, and procedure costs. We computed the 5-year incremental 
cost-effectiveness ratio (ICER) in euros per quality-adjusted life year (QALY), with 
costs and effects discounted at 3% per year. Results: SPG stimulation was pro-
jected to add 0.325 QALYs over the study period, while adding € 681 in cost, resulting 
in a 5-year ICER of € 2,097 per QALY gained. Longer follow-up periods, higher baseline 
attack frequency, and higher utilization of attack-aborting medications led to overall 
cost savings. SPG stimulation was found either cost-effective or cost-saving across 
all scenarios investigated in sensitivity analyses. ConClusions: Our model-based 
analysis suggests that SPG stimulation for the treatment of chronic cluster head-
ache, under the assumption of sustained therapy effectiveness, leads to meaningful 
gains in health-related quality of life and is a cost-effective treatment strategy in 
the German healthcare system.
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objeCtives: The objective was to study the economic and humanistic outcomes 
among acute coronary syndrome patients receiving percutaneous coronary inter-
vention (PCI) in a tertiary care setup in South India. Methods: Total 240 acute 
coronary syndrome patients visiting to tertiary care multispecialty hospital in south 
India were included in to the study from 2011 to 2013. Prior ethical approval was 
taken and patients were included after signing the consent form. All the patients 
included were receiving PCI first time. Socio-demographic, clinical diagnostic and 
risk factor data was collected using a pilot tested data collection sheet. EQ5D was 
used to collect the humanistic data on discharge, 1 month, 3 month, 6 month follow 
up. The cost incurred in the intervention and other direct costs were taken from the 
bill paid by the patient at discharge. SPSS 15.0 was used to analyse the collected data 
and demographic results were represented with descriptive statistics and Mann-
Whitney test was carried to compare the costs among both the groups. Repeated 
measures ANOVA was done to check the difference in VAS score in baseline and 
follow-up cases. Results: 80 percent of the patients were males and their mean 
age was 57.65 ±10.103 with 70 of them coming from rural background. Average 
monthly income of the patients receiving BMS and DES was found to be 10212.5 ± 
8750 and 12859.28 ± 7673.277 respectively. Almost half of the patients were having 
hypertension as a major co-morbid condition. Smoking, sedentary lifestyle and 
alcohol consumption ware predominant risk factors. Baseline EQ5D VAS scores were 
0.5054 ± 0.1848 and 0.4715 ± 0.1615 among patients receiving BMS and DES. There 
was a significant difference (p< 0.001) in the cost among the patients receiving both 
BMS and DES. ConClusions: There is a significant difference in the cost incurred 
and health related quality of life achieved among both groups due to disparity in 
economic status.
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objeCtives: To develop a system dynamics model with a stochastic component to 
analyse the cost-effectiveness of bacterial whole-genome sequencing (WGS) versus 
current typing methods to detect and monitor outbreaks of methicillin-resistant 
Staphylococcus aureus (MRSA) in the UK National Health Service (NHS). Methods: 
The model, developed in R, simulated a low-risk ward and a high-risk ward (e.g. an 
intensive care unit). Patients were assumed to move between three states: suscep-
tible, colonised, or infected (symptomatic). Healthcare workers were either uncon-
taminated or MRSA-colonised. Clinical inputs were identified from peer-reviewed 
primary research papers, systematic reviews, published models, data published 
by the NHS and from clinical experts. Relevant costs were identified from the 
Department of Health guidelines on MRSA infection management, and other pub-
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objeCtives: Estimate the economic impact derived from the use of antibiotic-
impregnated catheters vs. traditional, non-antibiotic-impregnated catheters for 
the treatment of hydrocephalus in pediatric patients with external shunts from 
a Mexican public hospital perspective (IMSS). Methods: An Excel-based deci-
sion tree was used to estimate the economic consequences of using an antibiotic-
impregnated catheter (treatment group) vs. a catheter without antibiotic (control 
group) for target population. Given procedure volume variability in comparable 
hospitals, base-case scenario assumed 100 pediatric patients with hydrocepha-
lus and only one potential infection after first catheter placement; the antibiotic-
impregnated device was assumed as second-line treatment for both groups. 
Infection rates after catheter placement for considered alternatives were taken 
from published international meta-analyses (2.4% vs. 8.7% for treatment and control 
groups, respectively). Unitary costs were provided by internal resources (antibiotic-
impregnated device) and by public bid results for base-case hospital (traditional 
catheter). Considered time horizon was < 1 year, thus no annual discount rate for 
costs was necessary. Inflation-adjusted DRGs from IMSS´s high specialty hospitals 
were used as hospitalization (catheter placement) and catheter replacement costs. 
Results are shown in 2015-adjusted USD. Due to low reinfection rates documented 
in literature, posterior infections and mortality were not considered. Results: 
The total cost of the catheter with antibiotic strategy resulted in $1,610,600, while 
the non-antibiotic catheter strategy in $1,542,200, resulting in additional $684 per 
patient treated with the antibiotic-impregnated device and $11,400 per avoided 
infection. ConClusions: The use of antibiotic-impregnated catheters appears to 
be a cost-effective alternative to treat hydrocephalus in pediatric patients in the 
Mexican setting. Local high-specialty hospitals should consider the adoption of this 
alternative as it yields less infections in target population.
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objeCtives: Deep brain stimulation (DBS), which uses an implantable device 
to modulate brain activity, has been shown to be clinically superior to medical 
therapy for treating advanced Parkinson’s disease. Our objective was to study the 
cost-utility of DBS in conjunction with medical therapy compared to best medical 
therapy (BMT) alone, using the latest clinical and cost data for the U.S. healthcare 
system. Methods: We used a decision-analytic state-transition (Markov) model 
to project Parkinson’s disease progression and associated costs for the two treat-
ment strategies. We estimated the discounted incremental cost-effectiveness ratio 
(ICER) in U.S. dollars per quality-adjusted life-year (QALY) from the Medicare payer 
perspective, considering a 10-year horizon. We evaluated the robustness of our 
projections through extensive deterministic sensitivity analyses. Results: Over 10 
years, DBS treatment led to discounted total costs of $129,345 compared to $91,026 
for BMT and added 1.69 QALYs more than BMT, resulting in an ICER of $22,713 per 
QALY. This ICER was relatively insensitive to variations in input parameters, with 
neurostimulator replacement timepoint, costs related to DBS implantation, and 
costs related to the treatment of disease-related falls having the greatest effects 
on the ratio. Across all investigated scenarios, including a 5-year horizon, ICERs 
remained under $50,000 per QALY. Longer follow-up periods and younger treatment 
age were associated with greater cost-effectiveness. ConClusions: Our findings 
suggest that DBS is a cost-effective treatment strategy in the U.S. healthcare sys-
tem across a wide range of assumptions. DBS yields substantial improvements in 
health-related quality of life at a value profile that compares favorably to other 
well-accepted therapies.
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objeCtives: To compare the real-world medical services utilization and associ-
ated costs of Medicare patients with diabetic foot ulcers (DFU) treated with either 
of the following two types of skin substitutes: bilayered living cellular construct 
(BLCC) or human fibroblast-derived dermal substitute (HFDS) with those receiving 
conventional care (CC). Methods: DFU patients were selected from Medicare de-
identified administrative claims using ICD-9-CM codes. The analysis followed an 
“intent-to-treat” design, with cohorts assigned based on use of (1) BLCC, (2) HFDS, or 
(3) CC (i.e., ≥ 1 claim for a DFU-related treatment procedure or podiatrist visit and no 
evidence of skin substitute use) for treatment of DFU in 2006-2012. Propensity score 
models were used to separately match BLCC and HFDS patients to CC patients with 
similar baseline demographics, wound severity, and physician experience measures. 
Medical resource use, lower-limb amputation rates, and total healthcare costs (2012 
USD; from payer perspective) during the 18 months following treatment initiation 
were compared separately among the two resulting matched samples. Results: 
Data for 502 matched BLCC-CC patient pairs and 222 matched HFDS-CC patient 
pairs were analyzed. Relative to matched CC patients, BLCC and HFDS patients 
had fewer days hospitalized (BLCC: -33.3% p< 0.01, HFDS: -42.4% p< 0.01) and fewer 
emergency department visits (BLCC: -32.3% p< 0.01, HFDS: -25.7% p< 0.01), as well 
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Maker (insightmaker.com), simulated a 33-bed ward. Patients were assumed to move 
between five states: susceptible, susceptible and vulnerable due to antimicrobial 
use, colonised, colonised and vulnerable, or infected (symptomatic). Clinical inputs 
were identified from peer-reviewed primary research papers, systematic reviews, 
published models, data published by the NHS and from clinical experts. Relevant 
costs were identified from Department of Health guidelines on C.diff infection man-
agement and other published sources, and inflated to 2014 values where necessary. 
We assumed that a fine of £10,000 per case was issued when evidence of hospital 
transmission was found, indicating that the infection was hospital-acquired; English 
hospitals are fined for hospital-acquired cases above an annual threshold, which 
varies between hospitals. Results: As a result of the low prevalence of C.diff, no 
outbreaks were observed over the one-year time horizon. There were 2.95 cases of 
C.diff in the base case, equivalent to 2.68 cases per 10,000 bed days. Fewer cases 
showed evidence of transmission when using WGS, which resulted in lower fines 
for the hospital (assuming a zero case tolerance policy). Annual C.diff-attributable 
costs for the ward were therefore £1,490 lower when WGS was used compared to 
ribotyping alone, although initial setup costs and service running costs were not 
included. ConClusions: This system dynamics model is the first formal attempt 
to evaluate the cost-effectiveness of WGS for monitoring connections between C.diff 
cases. Depending on the annual threshold for cases and the availability of WGS, 
initial results indicate that WGS may be cost-saving at a hospital level due to fewer 
cases being subject to a fine.
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objeCtives: Treatment for post dialysis infections imposes a significant eco-
nomic burden on the national health care system. The rate of hospitalization for 
bloodstream infections for Hemodialysis (HD) alone has increased 51 percent with 
an estimated cost in excess of $US 23,000 per hospitalization. The new bundled 
payments for care improvement (BPCI) initiative, promotes healthcare interven-
tions that improve patient outcomes at a lower cost. Peritoneal dialysis (PD) has 
been purported to lower the risk of bloodstream infections, which could poten-
tially reduce hospitalization costs. The purpose of this study was to estimate the 
cost per hospitalizations averted by substituting PD for HD. Methods: Data on 
treatment costs, and hospitalization rates for HD and PD were obtained from the 
USRDS registry. Using a payer perspective, a decision tree model was used to esti-
mate the ICER. Univariate sensitivity analysis was done to assess the robustness 
of the results. Results: Using PD was clearly cost-effective with an average cost 
of $50,320.08 per patient per year and resulted in 1,202 dialysis related hospitaliza-
tions; compared to HD which cost $69,916.28 per patient per year and resulted in 
1,462 dialysis-related hospitalizations. ConClusions: PD resulted in overall lower 
mean costs and hospitalization rates compared to HD. Considering the “payment 
for results” nature of the BPCI, PD has a high likelihood of being adopted as the 
preferred intervention in ESRD.
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objeCtives: To quantify the potential value of cerebrospinal fluid (CSF) biomarker 
testing for patients with mild cognitive impairment (MCI). Biomarkers provide 
information about a patient’s risk of developing AD and can allow for early tar-
geted interventions for those patients found to be at higher risk of AD than oth-
ers. Methods: We developed a state-transition Markov model to project lifetime 
AD-free life years, costs and quality-adjusted life years (QALYs). We conducted a 
cost-effectiveness analysis of using CSF biomarker testing combined with the sub-
sequent treatments to delay the clinical diagnosis of AD (test-treat) compared to 
no treatment, and treatment strategies. For the test-treat strategies, we considered 
treating by different levels of risk, varying from treating only the highest risk group 
to treating all but the lowest risk group (total 5 risk levels). We performed deter-
ministic and probabilistic sensitivity analyses (PSA) and conducted an expected 
value of perfect information (EVPI) analysis to estimate the value of eliminating 
uncertainty of all parameters. Results: We found that treating MCI patients by 
their risk levels produced extra 0.9-3.8 AD-free life months compared to no treat-
ment. Three out of four test-treat strategies were ruled out by extended dominance. 
No treatment resulted in the highest cost and the highest effectiveness, with an 
incremental cost-effectiveness ratio of $30,000 per QALY compared to treating all 
patients. No treatment was optimal in 63% of the PSA iterations over 37% of the 
treatment strategy at willingness to pay of $50,000/QALY. The total EVPI was $3,512 
per patient. ConClusions: This study illustrates the potential for early targeted 
interventions for MCI patients who are at increased risk of developing AD. The 
design of this model and the findings could also be used to guide further research 
evaluating the cost-effectiveness of other biomarkers used to identify MCI patients 
at increased risk of progression to AD.
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objeCtives: Cardiac rhythm diseases related to syncope are of increasing incidence 
and prevalence worldwide including Colombia. Diagnosing transient arrhythmia 
is difficult with short term monitoring methods. We sought to compare cost-effec-
lished sources. The zero tolerance MRSA policy set by NHS England, which includes 
financial sanctions, was implemented in the model. Results: Over a one-year 
time horizon, although prevalence was higher on the high-risk ward, outbreaks 
occurred most frequently on the low-risk ward due to the higher number of patients. 
Preliminary results indicate that fewer outbreaks were declared when using WGS to 
identify the MRSA strain compared to current methods, due to the increased sensi-
tivity of WGS in identifying unrelated MRSA strains and therefore classifying fewer 
concurrent colonisations/infections as ‘outbreaks’. Fewer outbreaks resulted in cost-
savings due mainly to a lower cost of fines, and therefore WGS is likely to be cost-
effective where the technology and infrastructure is available. ConClusions: This 
newly developed model is the first formal attempt to evaluate the cost-effectiveness 
of WGS for detecting and monitoring outbreaks of MRSA. Initial results indicate that 
WGS will be cost-effective due to fewer outbreaks being declared. Further planned 
developments include expanding the model to simulate a complete hospital, as 
well as including start-up costs of setting up WGS services.
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Rosselli D.1, Acosta A.1, Castañeda C.1, Ruiz-Patiño A.2, Ruiz R.1
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objeCtives: Neuromyelitis optica (NMO) or Devic disease is a rare chronic condition 
characterized by demyelinating lesions in the central nervous system. The aim of 
this study was to evaluate cost-effectiveness of the detection of antibodies against 
the protein aquaporin water channel 4 (AQP4) with cell-based assay (CBA), compared 
with ELISA, for the diagnosis of NMO in Colombia. Methods: A decision tree model 
was constructed to compare costs, correctly diagnosed cases and relapses averted in 
patients with clinical suspicion of NMO, that were subjected to diagnostic tests for 
the detection of AQP4 antibodies. The analysis was undertaken from a third-party 
payer perspective, one year time horizon (first year with the disease) taking all 
costs for treatment and relapses, in 2014 Colombian pesos, from official published 
prices (1 USD = 2,033 COP). Since the CBA kit is not available in Colombia (currently 
samples are processed abroad), the price was obtained from the manufacturer and 
set in a national laboratory. Clinical variables were from a systematic literature 
review. Univariate and probabilistic sensitivity analyses (a Monte Carlo simulating a 
cohort of 1000 patients) were conducted. Results: Identification of AQP4 antibod-
ies with CBA is a dominant strategy: more effective (855 correctly diagnosed patients 
compared with 765 detected by ELISA, and 130 avoided relapses), and less costly, 
with expected yearly costs per correctly diagnosed Devic patient of USD $14,658 
compared with $15,614 for ELISA. Using CBA may represent savings in terms of 
reduced costs of treating disease and relapse with hospitalization. ConClusions: 
AQP4 antibody identification by the CBA method is a cost-saving diagnostic test, 
dominant over the ELISA method.
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objeCtives: Stroke is the most severe and debilitating consequence of atrial fibril-
lation (AF), with many patients ranking the resultant disability as worse than death. 
Warfarin, the established first-line therapy, is effective at reducing ischemic stroke, 
but is associated with increased bleeding risk and lower quality of life (QoL). Left 
atrial appendage closure (LAAC) with the Watchman Device has been found to be 
superior to warfarin at reducing risk of stroke in AF patients. This analysis sought 
to assess the cost effectiveness of LAAC versus warfarin for stroke prevention in 
non-valvular AF from the perspective of the US Centers for Medicare and Medicaid 
Services (CMS). Methods: A Markov model was constructed comparing clinical 
outcomes, QoL, and total costs of LAAC versus warfarin using PROTECT AF 4-year 
data. All clinical events reported in PROTECT AF were modeled over 1-year incre-
ments for 20 years to determine time to cost effectiveness. The model was populated 
with a cohort of 10,000 70-year old patients with a mean CHADS2 score of 2. Cost 
data were taken from 2015 US DRGs. One-way and probabilistic sensitivity analy-
ses were performed. Results: LAAC patients were estimated to live an additional 
1.1 quality-adjusted life years (QALYs) compared to warfarin patients. By year six, 
LAAC was cost effective in terms of QALYs ($40,221/QALY ) and life years gained 
($45,610/LYG). LAAC was dominant over warfarin at 10 years and remained so for 
the 20-year time horizon. The probability of cost effectiveness at 10 years was 99% 
given a willingness-to-pay threshold of $50,000 per QALY. ConClusions: LAAC 
with the Watchman Device is a cost effective alternative to warfarin therapy for 
stroke risk reduction in non-valvular AF. LAAC provides improved QOL, increased 
life expectancy, and offers better value to CMS over a patient’s lifetime.
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objeCtives: To develop a system dynamics model to analyse the cost-effective-
ness of bacterial whole-genome sequencing (WGS) versus current typing methods 
(ribotyping) alone in monitoring outbreaks of Clostridium difficile (C.diff) in the UK 
National Health Service (NHS). Methods: The model, constructed using Insight 
